Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?

Aijaz Gundroo, Mareena Zachariah, Neeraj Singh, Rajeev Sharma

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Purpose of review Alemtuzumab (Campath) usage as a preconditioning agent in kidney transplantation has gained considerable interest in the recent future. Alemtuzumab is currently available only by special request from Sanofi through its Campath distribution program. It is restricted to transplant programs with prior and continued experience with the agent. There may be a resurgence of interest for the utilization of this agent because of its ease of administration, and less cost and comparable or improved outcome in comparison to other induction agents. Recent findings Alemtuzumab when combined with standard calcineurin inhibitor and mycophenolate mofetil is well tolerated and efficacious as an induction therapy and allows for long-term steroid avoidance in high-risk renal transplant recipients. Summary The transplant community has advanced through a learning curve with the use of alemtuzumab over time; starting from an agent that was tried out to induce proper tolerance, minimization of nephrotoxic calcineurin inhibitors, and currently as a comparable depletional therapy that can reduce acute rejection in high-risk kidney transplant recipients.

Original languageEnglish (US)
Pages (from-to)638-642
Number of pages5
JournalCurrent Opinion in Organ Transplantation
Volume20
Issue number6
DOIs
StatePublished - Dec 1 2015

Fingerprint

Kidney Transplantation
Mycophenolic Acid
Transplants
Kidney
Learning Curve
alemtuzumab
Steroids
Costs and Cost Analysis
Therapeutics
Transplant Recipients
Calcineurin Inhibitors

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Transplantation

Cite this

Gundroo, Aijaz ; Zachariah, Mareena ; Singh, Neeraj ; Sharma, Rajeev. / Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?. In: Current Opinion in Organ Transplantation. 2015 ; Vol. 20, No. 6. pp. 638-642.
@article{730aa2e0c4294573bfd57f4012b508b3,
title = "Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?",
abstract = "Purpose of review Alemtuzumab (Campath) usage as a preconditioning agent in kidney transplantation has gained considerable interest in the recent future. Alemtuzumab is currently available only by special request from Sanofi through its Campath distribution program. It is restricted to transplant programs with prior and continued experience with the agent. There may be a resurgence of interest for the utilization of this agent because of its ease of administration, and less cost and comparable or improved outcome in comparison to other induction agents. Recent findings Alemtuzumab when combined with standard calcineurin inhibitor and mycophenolate mofetil is well tolerated and efficacious as an induction therapy and allows for long-term steroid avoidance in high-risk renal transplant recipients. Summary The transplant community has advanced through a learning curve with the use of alemtuzumab over time; starting from an agent that was tried out to induce proper tolerance, minimization of nephrotoxic calcineurin inhibitors, and currently as a comparable depletional therapy that can reduce acute rejection in high-risk kidney transplant recipients.",
author = "Aijaz Gundroo and Mareena Zachariah and Neeraj Singh and Rajeev Sharma",
year = "2015",
month = "12",
day = "1",
doi = "10.1097/MOT.0000000000000255",
language = "English (US)",
volume = "20",
pages = "638--642",
journal = "Current Opinion in Organ Transplantation",
issn = "1087-2418",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future? / Gundroo, Aijaz; Zachariah, Mareena; Singh, Neeraj; Sharma, Rajeev.

In: Current Opinion in Organ Transplantation, Vol. 20, No. 6, 01.12.2015, p. 638-642.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Alemtuzumab (Campath-1H) experience in kidney transplantation what we have learned; current practices; and scope for the future?

AU - Gundroo, Aijaz

AU - Zachariah, Mareena

AU - Singh, Neeraj

AU - Sharma, Rajeev

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Purpose of review Alemtuzumab (Campath) usage as a preconditioning agent in kidney transplantation has gained considerable interest in the recent future. Alemtuzumab is currently available only by special request from Sanofi through its Campath distribution program. It is restricted to transplant programs with prior and continued experience with the agent. There may be a resurgence of interest for the utilization of this agent because of its ease of administration, and less cost and comparable or improved outcome in comparison to other induction agents. Recent findings Alemtuzumab when combined with standard calcineurin inhibitor and mycophenolate mofetil is well tolerated and efficacious as an induction therapy and allows for long-term steroid avoidance in high-risk renal transplant recipients. Summary The transplant community has advanced through a learning curve with the use of alemtuzumab over time; starting from an agent that was tried out to induce proper tolerance, minimization of nephrotoxic calcineurin inhibitors, and currently as a comparable depletional therapy that can reduce acute rejection in high-risk kidney transplant recipients.

AB - Purpose of review Alemtuzumab (Campath) usage as a preconditioning agent in kidney transplantation has gained considerable interest in the recent future. Alemtuzumab is currently available only by special request from Sanofi through its Campath distribution program. It is restricted to transplant programs with prior and continued experience with the agent. There may be a resurgence of interest for the utilization of this agent because of its ease of administration, and less cost and comparable or improved outcome in comparison to other induction agents. Recent findings Alemtuzumab when combined with standard calcineurin inhibitor and mycophenolate mofetil is well tolerated and efficacious as an induction therapy and allows for long-term steroid avoidance in high-risk renal transplant recipients. Summary The transplant community has advanced through a learning curve with the use of alemtuzumab over time; starting from an agent that was tried out to induce proper tolerance, minimization of nephrotoxic calcineurin inhibitors, and currently as a comparable depletional therapy that can reduce acute rejection in high-risk kidney transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=84961050724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961050724&partnerID=8YFLogxK

U2 - 10.1097/MOT.0000000000000255

DO - 10.1097/MOT.0000000000000255

M3 - Review article

VL - 20

SP - 638

EP - 642

JO - Current Opinion in Organ Transplantation

JF - Current Opinion in Organ Transplantation

SN - 1087-2418

IS - 6

ER -